CSL Stock Overview
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$264.52|
|52 Week High||AU$319.78|
|52 Week Low||AU$242.00|
|1 Month Change||-9.36%|
|3 Month Change||-10.59%|
|1 Year Change||-3.67%|
|3 Year Change||32.82%|
|5 Year Change||134.34%|
|Change since IPO||32,965.33%|
Recent News & Updates
Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?
Does the January share price for CSL Limited ( ASX:CSL ) reflect what it's really worth? Today, we will estimate the...
With EPS Growth And More, CSL (ASX:CSL) Is Interesting
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
|CSL||AU Biotechs||AU Market|
Return vs Industry: CSL matched the Australian Biotechs industry which returned -3.1% over the past year.
Return vs Market: CSL underperformed the Australian Market which returned 5.8% over the past year.
|CSL Average Weekly Movement||3.9%|
|Biotechs Industry Average Movement||9.1%|
|Market Average Movement||8.6%|
|10% most volatile stocks in AU Market||15.4%|
|10% least volatile stocks in AU Market||3.7%|
Stable Share Price: CSL is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: CSL's weekly volatility (4%) has been stable over the past year.
About the Company
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
CSL Fundamentals Summary
|CSL fundamental statistics|
Is CSL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CSL income statement (TTM)|
|Cost of Revenue||US$4.47b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Feb 16, 2022
|Earnings per share (EPS)||4.96|
|Net Profit Margin||23.04%|
How did CSL perform over the long term?See historical performance and comparison
1.1%Current Dividend Yield
Is CSL undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CSL (A$264.52) is trading above our estimate of fair value (A$238.38)
Significantly Below Fair Value: CSL is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CSL is poor value based on its PE Ratio (38.4x) compared to the Global Biotechs industry average (32.8x).
PE vs Market: CSL is poor value based on its PE Ratio (38.4x) compared to the Australian market (18.6x).
Price to Earnings Growth Ratio
PEG Ratio: CSL is poor value based on its PEG Ratio (4.5x)
Price to Book Ratio
PB vs Industry: CSL is overvalued based on its PB Ratio (10.9x) compared to the AU Biotechs industry average (4.2x).
How is CSL forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CSL's forecast earnings growth (8.5% per year) is above the savings rate (1.9%).
Earnings vs Market: CSL's earnings (8.5% per year) are forecast to grow slower than the Australian market (11.1% per year).
High Growth Earnings: CSL's earnings are forecast to grow, but not significantly.
Revenue vs Market: CSL's revenue (6.5% per year) is forecast to grow faster than the Australian market (4.8% per year).
High Growth Revenue: CSL's revenue (6.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CSL's Return on Equity is forecast to be high in 3 years time (26.1%)
How has CSL performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CSL has high quality earnings.
Growing Profit Margin: CSL's current net profit margins (23%) are higher than last year (23%).
Past Earnings Growth Analysis
Earnings Trend: CSL's earnings have grown by 14.4% per year over the past 5 years.
Accelerating Growth: CSL's earnings growth over the past year (13%) is below its 5-year average (14.4% per year).
Earnings vs Industry: CSL earnings growth over the past year (13%) underperformed the Biotechs industry 48.2%.
Return on Equity
High ROE: CSL's Return on Equity (28.3%) is considered high.
How is CSL's financial position?
Financial Position Analysis
Short Term Liabilities: CSL's short term assets ($7.4B) exceed its short term liabilities ($3.1B).
Long Term Liabilities: CSL's short term assets ($7.4B) exceed its long term liabilities ($6.7B).
Debt to Equity History and Analysis
Debt Level: CSL's net debt to equity ratio (33.4%) is considered satisfactory.
Reducing Debt: CSL's debt to equity ratio has reduced from 121.5% to 55% over the past 5 years.
Debt Coverage: CSL's debt is well covered by operating cash flow (78.6%).
Interest Coverage: CSL's interest payments on its debt are well covered by EBIT (20.2x coverage).
What is CSL current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CSL's dividend (1.08%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.25%).
High Dividend: CSL's dividend (1.08%) is low compared to the top 25% of dividend payers in the Australian market (5.52%).
Stability and Growth of Payments
Stable Dividend: CSL is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: CSL is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: CSL is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CSL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Perreault (64 yo)
Mr. Paul R. Perreault, B.A. (Psychology) has been the Chief Executive Officer and Managing Director of CSL Limited since July 1, 2013. Mr. Perreault serves as the Chief Executive Officer and Managing Direc...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD10.12M) is above average for companies of similar size in the Australian market ($USD3.78M).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
Experienced Management: CSL's management team is considered experienced (4.2 years average tenure).
Experienced Board: CSL's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CSL insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.2%.
CSL Limited's employee growth, exchange listings and data sources
- Name: CSL Limited
- Ticker: CSL
- Exchange: ASX
- Founded: 1916
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$126.639b
- Shares outstanding: 478.75m
- Website: https://www.csl.com.au
Number of Employees
- CSL Limited
- 45 Poplar Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/22 07:02|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.